Literature DB >> 28986619

[Therapeutic utilization of stem cells in orthopedics].

C Chiari1, S Walzer2, D Stelzeneder2, M Schreiner2, R Windhager2.   

Abstract

Stem cells are becoming increasingly more important in the field of regenerative medicine. Adult mesenchymal stem cells (MSCs) are harvested predominantly from bone marrow or adipose tissue, are already being used in the clinical setting and have a low potential for side effects. In orthopedics, experience has been gained in the treatment of bone defects, non-unions, cartilage defects, osteoarthritis and tendon pathologies. The current data are derived from case studies and randomized controlled trials are missing; therefore, there are many open questions concerning the optimal cell source, number of cells, administration technique (e.g. injections and matrices) or combinations with growth factors; however, it is evident from the data that MSCs have a positive effect on tissue regeneration and are safe to use.

Entities:  

Keywords:  Bone; Cartilage; Osteoarthritis; Regenerative medicine; Tendons

Mesh:

Year:  2017        PMID: 28986619     DOI: 10.1007/s00132-017-3475-6

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  65 in total

1.  Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells.

Authors:  Ph Hernigou; A Poignard; F Beaujean; H Rouard
Journal:  J Bone Joint Surg Am       Date:  2005-07       Impact factor: 5.284

2.  Identifying the optimum source of mesenchymal stem cells for use in knee surgery.

Authors:  Benjamin M Davies; Sarah J B Snelling; Lynn Quek; Osnat Hakimi; Hua Ye; Andrew Carr; Andrew J Price
Journal:  J Orthop Res       Date:  2017-03-02       Impact factor: 3.494

3.  Sequential differentiation of mesenchymal stem cells in an agarose scaffold promotes a physis-like zonal alignment of chondrocytes.

Authors:  Jacqueline Frida Schmitt; Kwee Hua See; See Kwee Hua; Zheng Yang; Yang Zheng; James Hoi Po Hui; James Hui Hoi Po; Eng Hin Lee; Lee Eng Hin
Journal:  J Orthop Res       Date:  2012-04-19       Impact factor: 3.494

4.  Treatment of Lateral Epicondylosis by Using Allogeneic Adipose-Derived Mesenchymal Stem Cells: A Pilot Study.

Authors:  Sang Yoon Lee; Won Kim; Chaiyoung Lim; Sun G Chung
Journal:  Stem Cells       Date:  2015-08-06       Impact factor: 6.277

5.  One-step repair in talar osteochondral lesions: 4-year clinical results and t2-mapping capability in outcome prediction.

Authors:  Sandro Giannini; Roberto Buda; Milva Battaglia; Marco Cavallo; Alberto Ruffilli; Laura Ramponi; Gherardo Pagliazzi; Francesca Vannini
Journal:  Am J Sports Med       Date:  2012-12-05       Impact factor: 6.202

Review 6.  Cell carriers as the next generation of cell therapy for cartilage repair: a review of the matrix-induced autologous chondrocyte implantation procedure.

Authors:  Mats Brittberg
Journal:  Am J Sports Med       Date:  2009-12-04       Impact factor: 6.202

7.  The transtrochanteric anterior rotational osteotomy of Sugioka. Early and late results in idiopathic aseptic femoral head necrosis.

Authors:  R Eyb; R Kotz
Journal:  Arch Orthop Trauma Surg       Date:  1987

8.  Matrix-Induced Autologous Chondrocyte Implantation versus Multipotent Stem Cells for the Treatment of Large Patellofemoral Chondral Lesions: A Nonrandomized Prospective Trial.

Authors:  Alberto Gobbi; Sanyam Chaurasia; Georgios Karnatzikos; Norimasa Nakamura
Journal:  Cartilage       Date:  2015-04       Impact factor: 4.634

9.  Mesenchymal stem cells.

Authors:  A I Caplan
Journal:  J Orthop Res       Date:  1991-09       Impact factor: 3.494

10.  Stem cell implantation for osteonecrosis of the femoral head.

Authors:  Young Wook Lim; Yong Sik Kim; Jong Wook Lee; Soon Yong Kwon
Journal:  Exp Mol Med       Date:  2013-11-15       Impact factor: 8.718

View more
  1 in total

1.  Regenerative medicine in cardiothoracic surgery: do the benefits outweigh the risks?

Authors:  Francesco Petrella
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.